Jacobs Levy Equity Management Inc. Has $4.13 Million Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Jacobs Levy Equity Management Inc. reduced its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 23.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 438,463 shares of the biopharmaceutical company's stock after selling 137,984 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.89% of Theravance Biopharma worth $4,126,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TBPH. Barclays PLC lifted its stake in shares of Theravance Biopharma by 279.9% during the third quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company's stock valued at $529,000 after buying an additional 48,316 shares during the period. JPMorgan Chase & Co. raised its stake in Theravance Biopharma by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company's stock worth $2,151,000 after purchasing an additional 7,620 shares during the period. SG Americas Securities LLC raised its stake in Theravance Biopharma by 21.1% during the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company's stock worth $181,000 after purchasing an additional 3,349 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Theravance Biopharma by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock worth $2,766,000 after purchasing an additional 2,060 shares during the period. Finally, Teacher Retirement System of Texas purchased a new position in Theravance Biopharma during the fourth quarter worth approximately $103,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Price Performance

Shares of TBPH traded down $0.04 during mid-day trading on Tuesday, hitting $9.36. The company's stock had a trading volume of 39,875 shares, compared to its average volume of 272,487. The firm has a 50-day moving average price of $9.16 and a 200 day moving average price of $9.32. The stock has a market capitalization of $467.76 million, a price-to-earnings ratio of -9.27 and a beta of -0.10. Theravance Biopharma, Inc. has a fifty-two week low of $7.44 and a fifty-two week high of $10.90.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The firm had revenue of $15.39 million during the quarter, compared to analysts' expectations of $28.08 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. As a group, equities analysts anticipate that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on TBPH shares. StockNews.com raised shares of Theravance Biopharma from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. HC Wainwright reiterated a "buy" rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Theravance Biopharma currently has an average rating of "Hold" and a consensus price target of $11.33.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 370,038 shares in the company, valued at $3,330,342. The trade was a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.90% of the stock is currently owned by corporate insiders.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.